Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 2/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | MARS1 | P56192 | 1/20 | 0.53 |
| ▸ | IARS1 | P41252 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29047905 | 0.88 | ADORA2A (0.60) | — | |
| SCHEMBL29047902 | 0.88 | ADORA2A (0.60) | — | |
| SCHEMBL2988353 | 0.88 | P2RY12 (0.68) | TARS1ADORA1P2RY12 | |
| SCHEMBL574739 | 0.86 | P2RY1 (0.50) | TARS1P2RY12 | |
| SCHEMBL17627817 | 0.85 | PRKACA (0.56) | ADORA1PRMT5WDR77PRKACAP2RY12 | |
| SCHEMBL2033392 | 0.85 | TARS1 (0.60) | TARS1ADORA1IARS1PRMT5WDR77 | |
| SCHEMBL2990348 | 0.83 | P2RY12 (0.68) | ADORA1P2RY12 | |
| SCHEMBL2056705 | 0.83 | ADORA3 (0.60) | TARS1ADORA1PRMT5WDR77DOT1L | |
| SCHEMBL19462601 | 0.83 | TARS1 (0.55) | TARS1ADORA1MARS1IARS1PRKACA | |
| SCHEMBL17371761 | 0.83 | TARS1 (0.58) | TARS1MARS1IARS1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240230622-A9 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240133865-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2024-04-25 | — | — | US | disclosed |
| US-11674948-B2 | Methods and systems for determining autism spectrum disorder risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2023-06-13 | — | — | US | disclosed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200103417-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2020-04-02 | — | — | US | disclosed |
| EP-3554268-A1 | COMPOSITIONS AND METHODS FOR SMALL CANINES | Société des Produits Nestlé S.A. (CH) | 2019-10-23 | — | — | EP | disclosed |
| US-20190310269-A1 | SYSTEMS AND METHODS FOR MEASURING OBESITY USING METABOLOME ANALYSIS | HUMAN LONGEVITY, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10405564-B2 | Compositions and methods for small canines | Societe des Produits Westle S.A. (CH) | 2019-09-10 | — | — | US | disclosed |
| US-10254272-B2 | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease | Global Genomics Group, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180348199-A1 | Methods and Systems for Determining Autism Spectrum Disorder Risk | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180168193-A1 | COMPOSITIONS AND METHODS FOR SMALL CANINES | Société des Produits Nestlé S.A. (CH) | 2018-06-21 | — | — | US | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | Global Genomics Group, LLC | 2016-07-14 | — | — | US | disclosed |
| US-20160116486-A1 | BIOMARKERS RELATED TO KIDNEY FUNCTION AND METHODS USING THE SAME | METABOLON, INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | TARS1 4822/4885ADORA1 3/4885MARS1 2194/4885 |
| US-20160202239-A1 | BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE | FABP3, APOB, CAD | TARS1 4172/4885ADORA1 1468/4885MARS1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.